UA86528C2 - Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону - Google Patents

Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону

Info

Publication number
UA86528C2
UA86528C2 UAA200713931A UAA200713931A UA86528C2 UA 86528 C2 UA86528 C2 UA 86528C2 UA A200713931 A UAA200713931 A UA A200713931A UA A200713931 A UAA200713931 A UA A200713931A UA 86528 C2 UA86528 C2 UA 86528C2
Authority
UA
Ukraine
Prior art keywords
pyrazolopyrimidine derivative
prevention
treatment
liver diseases
present
Prior art date
Application number
UAA200713931A
Other languages
English (en)
Russian (ru)
Inventor
Сєул Мінь Чой
Б'янг Ок Ан
Мухі Ю
Original Assignee
Донг-А Фармацевтікал.Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Донг-А Фармацевтікал.Ко., Лтд. filed Critical Донг-А Фармацевтікал.Ко., Лтд.
Publication of UA86528C2 publication Critical patent/UA86528C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Даний винахід стосується фармацевтичної композиції для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону, як активний інгредієнт. За даним винаходом похідна піразолопіримідинону має значний ефект на інгібування синтезу колагену в зірчастих клітинах печінки та діє безпосередньо на портальну вену. Зокрема, можна збільшити її діаметр та посилити потік крові портальної вени та, в результаті, знизити її тиск. Тому, похідну піразолопіримідинону можна застосовувати переважно для попередження та лікування фіброзу печінки, цирозу печінки, спричиненого фіброзом печінки, портальної гіпертензії та різних ускладнень, спричинених портальною гіпертензією. Крім того, похідна піразолопіримідинону за даним винаходом може знизити частоту дозування, тому що у неї довгий період напіввиведення, та тому, що вона має перевагу покращення режиму прийому лікарського засобу пацієнтами, що страждають на хронічні хвороби печінки.
UAA200713931A 2005-06-10 2005-10-21 Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону UA86528C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050050033 2005-06-10
PCT/KR2005/003526 WO2006132460A1 (en) 2005-06-10 2005-10-21 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Publications (1)

Publication Number Publication Date
UA86528C2 true UA86528C2 (uk) 2009-04-27

Family

ID=37498629

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200713931A UA86528C2 (uk) 2005-06-10 2005-10-21 Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону

Country Status (22)

Country Link
US (1) US8796286B2 (uk)
EP (1) EP1888074B1 (uk)
JP (1) JP4879977B2 (uk)
KR (1) KR100914445B1 (uk)
CN (1) CN101193636B (uk)
AT (1) ATE537832T1 (uk)
AU (1) AU2005332719B2 (uk)
BR (1) BRPI0520209A2 (uk)
CA (1) CA2611638C (uk)
CY (1) CY1112637T1 (uk)
DK (1) DK1888074T3 (uk)
ES (1) ES2376628T3 (uk)
HK (1) HK1119596A1 (uk)
IL (1) IL187678A (uk)
MX (1) MX2007015365A (uk)
NO (1) NO20076053L (uk)
NZ (1) NZ564369A (uk)
PT (1) PT1888074E (uk)
RU (1) RU2369392C2 (uk)
UA (1) UA86528C2 (uk)
WO (1) WO2006132460A1 (uk)
ZA (1) ZA200800180B (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322917A1 (en) * 2006-12-28 2010-12-23 Insect Biotech Co., Ltd. Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2873017B1 (en) 2012-07-11 2021-09-01 University of Mississippi Medical Center Method for the detection and staging of liver fibrosis from image acquired data
ES2848348T3 (es) 2014-05-16 2021-08-06 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
KR102448406B1 (ko) 2015-06-30 2022-09-27 큠버랜드 파마슈티컬즈 인코포레이티드 Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
AU2017263462B2 (en) 2016-05-11 2021-05-13 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CA3229274A1 (en) * 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100377782B1 (ko) 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
WO2004037183A2 (en) 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja) 2003-05-15 2004-12-16 Kumiai Chemical Industry Co., Ltd. フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
JP2006527257A (ja) * 2003-06-10 2006-11-30 ファイザー・インク 月経困難症の治療用のｐｄｅ阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren

Also Published As

Publication number Publication date
CA2611638A1 (en) 2006-12-14
JP2008543748A (ja) 2008-12-04
IL187678A (en) 2013-04-30
EP1888074A4 (en) 2010-06-23
KR100914445B1 (ko) 2009-08-28
RU2369392C2 (ru) 2009-10-10
RU2007149474A (ru) 2009-07-20
KR20060128605A (ko) 2006-12-14
NO20076053L (no) 2008-02-27
JP4879977B2 (ja) 2012-02-22
WO2006132460A1 (en) 2006-12-14
IL187678A0 (en) 2008-11-03
AU2005332719A1 (en) 2006-12-14
HK1119596A1 (en) 2009-03-13
EP1888074B1 (en) 2011-12-21
AU2005332719B2 (en) 2010-05-13
PT1888074E (pt) 2012-03-01
EP1888074A1 (en) 2008-02-20
CY1112637T1 (el) 2016-02-10
MX2007015365A (es) 2008-02-12
ATE537832T1 (de) 2012-01-15
US20080207646A1 (en) 2008-08-28
ZA200800180B (en) 2009-01-28
CN101193636A (zh) 2008-06-04
DK1888074T3 (da) 2012-01-23
CA2611638C (en) 2010-08-24
US8796286B2 (en) 2014-08-05
BRPI0520209A2 (pt) 2009-04-22
CN101193636B (zh) 2011-12-28
NZ564369A (en) 2010-03-26
ES2376628T3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
UA86528C2 (uk) Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
GEP20125565B (en) Lactam compounds and their pharmaceutical use
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2005094897A3 (en) Pegylated ion channel modulating compounds
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MX2009011900A (es) Curacion de herida diabetica.
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2009120885A3 (en) Stabilizing lipid compositions for oral pharmaceutical agents
IL191670A0 (en) Compounds for the inhibition of apoptosis
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
MY148300A (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
SE0303135D0 (sv) Controlled food effect composition
SE0203817D0 (sv) New composition
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
TW200633722A (en) Complexes made using low solubility drugs